NovaBridge Biosciences (NBP) H.C. Wainwright 27th Annual Global Investment Conference summary

Strategic focus and financial position

• Shifted operations to focus exclusively on the U.S. market, divesting China operations.

• Maintains a strong cash position of $227 million, providing runway through Q4 2028.

• Pipeline includes three clinical-stage assets: Jeva Stomach, Raja Stomach, and Uli Ledla Mab.

• Recent investments are expanding Jeva Stomach programs and supporting a phase two trial launch by Q1 2026.

Clinical development and trial progress

• Jeva Stomach is a Claudin 18.2 therapeutic targeting front-line metastatic gastric cancer.

• Phase one dose expansion study completed recruitment, with data to be presented publicly in Q1 next year.

• Phase two randomized study (180 patients) to begin in Q1 next year, with PFS as the primary endpoint and readout expected in 2027.

• Recruitment rate for phase one exceeded historical norms by eightfold, reflecting strong investigator enthusiasm.

Competitive positioning and differentiation

• Jeva Stomach eligibility threshold is 1% Claudin 18.2 expression, potentially doubling the eligible patient pool compared to Zolbetuximab.

• Demonstrates higher binding affinity to Claudin 18.2 and a cleaner safety profile with no high-grade nausea or vomiting.

• Lower rates of grade 3+ adverse events compared to ADCs and T cell engagers, supporting front-line use.

• ORR of 18% as monotherapy and up to 83% in combination with Nivolumab plus FOLFOX in dose expansion cohorts.